ARMP:NYE-Armata Pharmaceuticals Inc (USD)

COMMON STOCK | Biotechnology | NYE

Last Closing Price

USD 3.82

Change

-0.01 (-0.26)%

Market Cap

USD 0.10B

Volume

7.43K

Avg Analyst Target

USD 7.00 (+83.25%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Armata Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for the treatment of antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for the treatment of Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has a partnership agreement with Merck & Co. for developing proprietary synthetic phage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California. Address: 4503 Glencoe Avenue, Marina del Rey, CA, United States, 90292

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-08-02 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NVO Novo Nordisk A/S

+0.40 (+0.43%)

USD212.61B 31.49 3.55
BHVN Biohaven Pharmaceutical Holdin..

-7.18 (-5.70%)

USD8.20B N/A N/A
RCUS Arcus Biosciences, Inc

-1.36 (-4.33%)

USD2.23B N/A N/A
MYOV Myovant Sciences Ltd

+0.43 (+2.10%)

USD1.89B N/A N/A
ADCT ADC Therapeutics SA

-0.33 (-1.57%)

USD1.65B -99,999.99 N/A
ZYME Zymeworks Inc

-0.05 (-0.16%)

USD1.51B 300.20 N/A
RFL Rafael Holdings, Inc

-0.98 (-1.94%)

USD0.90B N/A N/A
AMAM Ambrx Biopharma Inc.

+0.35 (+1.79%)

USD0.74B N/A N/A
PFNX Pfenex Inc

N/A

USD0.44B 268.67 63.90
LCTX Lineage Cell Therapeutics, Inc

-0.04 (-1.52%)

USD0.43B 3.63 N/A

ETFs Containing ARMP

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 28.19% 67% D+ 82% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 28.19% 67% D+ 80% B-
Trailing 12 Months  
Capital Gain -3.29% 63% D 11% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -3.29% 63% D 10% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 3.95% 30% F 49% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 3.95% 30% F 36% F
Risk Return Profile  
Volatility (Standard Deviation) 21.44% 85% B 51% F
Risk Adjusted Return 18.41% 30% F 29% F
Market Capitalization 0.10B 36% F 15% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 2.81 63% D 36% F
Price / Cash Flow Ratio -5.23 36% F 86% B
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -66.96% 40% F 10% F
Return on Invested Capital -126.34% 36% F 1% F
Return on Assets -28.50% 43% F 1% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 4.42 50% F 19% F
Short Percent 0.47% 93% A 86% B
Beta 0.16 88% B+ 93% A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector